Human Carbohydrate Antigen (CA) 15-3 ELISA kit

CAT#: EA100885

Human Carbohydrate Antigen (CA) 15-3 ELISA kit

Specifications

Product Data

• Format: 8x12 divisible strips
• Assay Type: Solid Phase Sandwich ELISA
• Assay Length: 3 hours
• Signal: Colorimetric
• Curve Range: 15-240 U/mL
• Sample Type: Serum
• Sample Volume: 200 µl/well
• Specificity: This kit is used for quantitative detection human human Carbohydrate Antigen (CA) 15-3
• Sensitivity: 15 U/mL
• Reactivities: Human
• Cross Reactivity: There is no detectable cross-reactivity with other relevant proteins.
• Interference: No significant interference observed with available related molecules.
• Components:
  • 1. Microwells coated with muriine monoclonal Anti-CA15-3: 12x8x1
  • 2. Sample Diluent: 100ml
  • 3. Enzyme Conjugate Concentrate (22X): 1 ml
  • 4. Enzyme Conjugate Diluent: 21 ml
  • 5. CA 15-3 Standards 6 vials: 2 ml
  • 6. TMB Solution: 11 ml
  • 7. Stop Solution: 11 ml
  • 8. Wash Concentrate 20x: 1 Bottle: 25 ml
• Background: Breast cancer is the most common life-threatening malignant lesion in women of many developed countries today, with approximately 180,000 new cases diagnosed every year. Roughly half of these newly diagnosed patients are node-negative, however 30% of these cases progress to metastatic disease. There are a number of tumor markers that can help clinicians to identify and diagnose which breast cancer patients will have aggressive disease and which will have an indolent course. These markers include estrogen and progesterone receptors, DNA ploidy and percent-S phase profile, epidermal growth factor receptor, HER-2/neu oncogene, p53 tumor suppressor gene, cathepsin D, proliferation markers and CA15-3. CA15-3 is most useful for monitoring patients post-operatively for recurrence, particularly metastatic diseases. 96% of patients with local and systemic recurrence have elevated CA15-3, which can be used to predict recurrence earlier than radiological and clinical criteria. A 25% increase in the serum CA15-3 is associated with progression of carcinoma. A 50% decrease in serum CA15-3 is associated with response to treatment. CA15-3 is more sensitive than CEA in early detection of breast cancer recurrence. In combination with CA125, CA15-3 has been shown to be useful in early detection of relapse of ovarian cancer. CA15-3 levels are also increased in colon, lung and hepatic tumors.
• Gene Symbol: MUC1